Cargando...
Lenalidomide for refractory cutaneous manifestations of paediatric systemic lupus erythematosus
OBJECTIVE: Cutaneous manifestations of paediatric systemic lupus erythematosus (pSLE) cause significant morbidity. Lenalidomide, a thalidomide analogue, has shown promise treating cutaneous LE (CLE) in adults. Our objective was to evaluate lenalidomide's efficacy and safety in treating refracto...
Guardado en:
| Publicado en: | Lupus |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5388573/ https://ncbi.nlm.nih.gov/pubmed/27837194 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0961203316676377 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|